Navigation Links
Osteopontin: a useful biomarker in asbestos-related cancer

Pleural mesothelioma is an asbestos-related cancer that invades the chest cavity and the lining of the lungs. Workers at risk for high levels of exposure are miners, factory workers, carpenters, electricians//, ship fitters, ships' electricians, boilermakers, insulation manufacturers, railroad workers, gas-mask manufacturers, and pipe insulators.

Recently, a study, published in the October 13 issue of New England Journal of Medicine, was conducted to test the hypothesis that osteopontin is a useful biomarker in pleural mesothelioma and, more specifically, to compare serum levels of osteopontin in a cohort of subjects with asbestos-related biomarker disease with preoperative levels in patients with surgically treated pleural mesothelioma. Osteopontin is a glycoprotein that is over expressed in lung, breast, colorectal, gastric, and ovarian cancer and in melanoma. High levels of osteopontin have previously been shown to correlate with tumor invasion, progression, and metastases.

The researchers investigated the presence of osteopontin in pleural mesothelioma and determined serum osteopontin levels in three populations: subjects without cancer who were exposed to asbestos, subjects without cancer who were not exposed to asbestos, and patients with pleural mesothelioma who were exposed to asbestos.

For the study, a group of 69 subjects with asbestos-related nonmalignant pulmonary disease were compared with 45 subjects without exposure to asbestos and 76 patients with surgically staged pleural mesothelioma. Tumor tissue was examined for osteopontin by immunohistochemical analysis, and serum osteopontin levels were measured by an enzyme-linked immunosorbent assay.

Serum osteopontin levels were found to be significantly higher in the group with pleural mesothelioma than in the group with exposure to asbestos. Immunohistochemical analysis revealed osteopontin staining of the tumor cells in 36 of 38 samples of pleural mesothelioma.
Data from this study suggest that serum osteopontin levels could be used to discriminate between persons with exposure to asbestos who do not have early pleural mesothelioma and those with exposure to asbestos who do have early pleural mesothelioma, regardless of the histologic type of the mesothelioma.

The authors point out that the most important result of this study is the apparent ability of an enzyme-linked immunosorbent assay (ELISA) for osteopontin to identify early pleural mesothelioma (stage I). Also, the finding that osteopontin was present in the tumor cells of pleural mesothelioma and not in the stroma provides support for the specificity of osteopontin as a marker for transformed mesothelial cells. This finding, if confirmed, would have immediate clinical applications, because the use of therapy could potentially influence survival among patients with stage I pleural mesothelioma.
'"/>




Related medicine news :

1. ATG useful in transplant patients as substitute for steroids
2. Vitamin E useful for Alzheimers
3. Carboplatin, Lung cancer drug may be useful in treating breast tumor
4. Vitamin B12 can help in detecting cancers
5. Want skin cancer? Please have a cigarette
6. New hope for cancer victims – will vaccine cure the deadly bug
7. Clintons new problem - Is the outgoing American president suffering from skin cancer?
8. Are cancer patients being taken for a ride?
9. Breast cancer treatment to be determined by gene test
10. Ductal lavage may detect early breast cancer
11. Beware of the oral patch! It could be cancer!!!
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to host ... items from across the nation, this holiday-themed event will raise funds and awareness for ... The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 p.m.) ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... 12, 2017 , ... Women-owned and Grand Rapids-based workplace wellness ... in Wellness® by Best and Brightest. OnSite Wellness will be honored at the ... 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located at ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... INDIANAPOLIS , Oct. 2, 2017  Eli Lilly ... its financial results for the third quarter of 2017 ... a conference call on that day with the investment ... performance. The conference call will begin at ... public can access a live webcast of the conference ...
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the ... analysis system called the HORIZON at MIBio 2017 in ... subvisible and visible particulate matter in biopharmaceutical samples with unprecedented speed ... of the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host ... webcast on Friday, November 3, 2017, beginning at 7:00 ... approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... performance and guidance for 2018, Hill-Rom executives will also ... performance, and long-range financial outlook through 2020. ...
Breaking Medicine Technology: